Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2012

View Archived Issues

AEOL-10150 demonstrates neuroprotective effects in rat model

Computational model includes all molecular components and interactions of pathogen's life cycle

Phase I/II trial assesses ROSE-010 in IBS-C

Vivalis synthesizes new candidate hepatitis therapies

New colimycin biosynthesis genes patented

Zetonna launched in U.S.

Omeros discovers key proteins in MASP-2 program

Novel protein kinase inhibitors disclosed by Leo Pharma

Phase I ALS-2200 data disclosed

Chinese researchers present new candidate cancer drugs

Novel tubulin polymerization inhibitors patented by group in Taiwan

U.S. university patents novel mGlu5 receptor modulators

Torii Pharmaceutical launches new Mitizax trials in Japan

La Jolla Pharmaceutical gives update on GCS-100 plans

Transgene and Tasly Pharmaceutical form joint venture

APP gene variant linked to reduced cognitive decline

FDA accepts Zelrix NDA resubmission for filing

CytoDyn to acquire antibody inhibiting HIV entry

Oncobiologics to utilize Xoma antibody technology platform

Second phase of malaria grant awarded to PolyMedix

MolecularMD seeks approval for companion diagnostic test

GenSpera's lead product clear to advance to phase II testing

Clinical proof of concept demonstrated for SCY-635

Recruitment complete in pivotal CRUISE trials

EryDel product receives orphan drug status for ataxia telangiectasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...